Bihua Chen
Direktor/Vorstandsmitglied bei BIOMEA FUSION, INC.
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kendra Adams | F | 48 | 4 Jahre | |
| Ramses Erdtmann | M | 60 | 7 Jahre | |
| Jing Rong Cui | M | 60 |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
| Mariam Maghribi | M | - |
Atia Vision, Inc.
 Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | 12 Jahre |
| Kenneth Anderson | M | 72 | 9 Jahre | |
| Tom Butler | M | 43 | 7 Jahre | |
| Bruce Downey | M | 76 | 9 Jahre | |
| Andrew Hirsch | M | 53 | 4 Jahre | |
| Claudio Argento | M | - |
Atia Vision, Inc.
Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | 12 Jahre |
| Laura Bessen | M | 61 | 2 Jahre | |
| Vic Myer | M | - |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 4 Jahre |
| Steve Morris | M | - | 4 Jahre | |
| Jean Liu | F | 55 | 2 Jahre | |
| Julie Hambleton | M | 66 | 3 Jahre | |
| Elizabeth Faust | M | 59 | 2 Jahre | |
| Franco Valle | M | 43 | 3 Jahre | |
| Catherine Stehman-Breen | M | 61 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 4 Jahre |
| Malcolm Salter | M | 84 | 9 Jahre | |
| Michael Hitchcock | M | 74 | 3 Jahre | |
| Utpal Koppikar | M | 53 | 2 Jahre | |
| Jolie Siegel | F | 47 | 4 Jahre | |
| Naomi Cretcher | F | - | 17 Jahre | |
| Yi Shan Li | M | 59 |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | 4 Jahre |
| Nikolai Kley | M | - |
Orionis Biosciences BV
 Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | 9 Jahre |
| Eric Aguiar | M | 62 | 4 Jahre | |
| George Golumbeski | M | 67 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 2 Jahre |
| Glenn Dubin | M | 67 | 3 Jahre | |
| Ebun Garner | M | 52 | 3 Jahre | |
| Amr Salahieh | M | - |
Atia Vision, Inc.
Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
| Donna Grogan | M | 67 | 2 Jahre | |
| Sumita Ray | F | 50 | 3 Jahre | |
| Min Hua | M | 73 |
Fudan University
| 34 Jahre |
| Owen Hughes | M | 49 | 1 Jahre | |
| Anthony Souza | M | - | 9 Jahre | |
| Terrie Phan | F | - | 3 Jahre | |
| Thorsten Kirschberg | M | 54 | 4 Jahre | |
| Hanna Cho | M | - | - | |
| Mayra Reyes-Armour | M | - | 3 Jahre | |
| Chun Yi Zhao | M | - | 2 Jahre | |
| Thomas Cahill | M | - |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Caleb Tripp | M | 38 |
Cormorant Asset Management LLC/Private Equity/
 Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 3 Jahre |
| Priyanka Mandava | F | - | - | |
| Cecilia Fernandez | F | - |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Raymond Kelleher | M | - |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 4 Jahre |
| Lisa Tesvich-Bonora | M | - | 2 Jahre | |
| Amy Grekowicz Parker | F | - | 2 Jahre | |
| Alex Cacovean | M | - | 3 Jahre | |
| Shannon Morris | M | 54 | 2 Jahre | |
| Courtney Solberg | F | - | - | |
| Scott Boyle | M | 46 | 2 Jahre | |
| Henry Chen | M | 53 |
Atia Vision, Inc.
Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
| Stewart Fisher | M | 57 | 8 Jahre | |
| M. Isabel Chiu | M | - | 8 Jahre | |
| Michael Kelly | M | 67 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 1 Jahre |
| Carl Gordon | M | 59 |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
| Kevin Bitterman | M | 47 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Steve Gullans | M | 71 |
Orionis Biosciences BV
Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | - |
| George Lee | M | 73 |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | - |
| Brett Ilan Kaplan | M | 50 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Kelly Schick | F | 44 | 3 Jahre | |
| Heow Tan | M | 65 | 4 Jahre | |
| Leonard Reyno | M | 61 | 1 Jahre | |
| Paola Pozzi | F | - |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Jeffrey D. Marrazzo | M | 46 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | 2 Jahre |
| Griet Vanpoucke | M | - |
Orionis Biosciences BV
Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | 9 Jahre |
| Todd Sinai | M | 54 |
The Wharton School of the University of Pennsylvania
| 27 Jahre |
| Janet Caroline Smith | F | 59 |
Putnam U.S. Holdings I LLC
 Putnam U.S. Holdings I LLC Investment ManagersFinance Putnam Investments LLC operates as an investment advisory company. The company was founded on May 14, 2009 and is headquartered in Boston, MA. | 23 Jahre |
| Juan Frias | M | - | 1 Jahre | |
| Michael Zelefsky | M | 63 |
Weill Cornell Medical College
| 30 Jahre |
| Casey Gordon | M | - |
Atia Vision, Inc.
Atia Vision, Inc. Electronic Equipment/InstrumentsElectronic Technology Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA. | - |
| Adrian Bignami | M | - | 3 Jahre | |
| Thomas Cahill | M | 37 |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | - |
| Mark Mossler | M | 51 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Andrew Phillips | M | 53 | 4 Jahre | |
| Marc A. Cohen | M | 61 | 7 Jahre | |
| Lauren White | F | 45 | 2 Jahre | |
| William McKee | M | 62 | 1 Jahre | |
| Yu Ming Zhang | M | 62 |
Fudan University
| 11 Jahre |
| Jason S. Fisherman | M | 67 | - | |
| Ken J. Ruskin | M | - |
Putnam U.S. Holdings I LLC
Putnam U.S. Holdings I LLC Investment ManagersFinance Putnam Investments LLC operates as an investment advisory company. The company was founded on May 14, 2009 and is headquartered in Boston, MA. | 4 Jahre |
| Pranav Gupta | M | - |
The Wharton School of the University of Pennsylvania
| 13 Jahre |
| Kah Poh Tan | M | 38 | - | |
| William Ogrodnick | M | - |
The Wharton School of the University of Pennsylvania
| 10 Jahre |
| Jie Qiu Wan | M | 69 |
Fudan University
| 15 Jahre |
| Li Jun Lin | M | 51 |
Fudan University
| 7 Jahre |
| Qing Yu Wang | M | 65 |
Fudan University
| 4 Jahre |
| Xiong Wen Lu | M | 58 |
Fudan University
| 6 Jahre |
| Alain J. Cohen | M | 57 | 7 Jahre | |
| Michael Robert Gelband | M | - |
Millennium Management LLC
 Millennium Management LLC Investment ManagersFinance Millennium Management LLC is a SEC-investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Israel 'Izzy' Englander in 1989 and is a subsidiary of MLM Trust B LLC, itself a subsidiary of MLM Trust B. Millennium Management provides discretionary investment advisory services to private investment funds. | - |
| Abbas M. Hasan | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Xin Hao Jiang | M | 59 |
Fudan University
| 7 Jahre |
| Will Lewis | M | 55 | - | |
| Alex Lloyd | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Rashad Rahman | M | - |
The Wharton School of the University of Pennsylvania
| 15 Jahre |
| Feng Yu | M | 60 |
Fudan University
| 6 Jahre |
| John Schmid | M | 61 | 2 Jahre | |
| Neal Rosenberg | M | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Elena Prokupets | M | 69 | 7 Jahre | |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 Jahre |
| John Kwon | M | 50 | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 89 | 89,00% |
| China | 8 | 8,00% |
| Belgien | 3 | 3,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bihua Chen
- Persönliches Netzwerk
